摘要
目的探讨莫西沙星与头孢哌酮舒巴坦联合替硝唑治疗急性肺脓肿的临床疗效及安全性。方法根据随机数字表法进行2017年1月至2018年4月90例急性肺脓肿患者分成2组。头孢哌酮舒巴坦联合替硝唑治疗组给予头孢哌酮舒巴坦联合替硝唑治疗,莫西沙星治疗组则给予莫西沙星治疗。比较两组急性肺脓肿治疗转归效果;退热时间、恢复正常血常规时间、致病菌清除时间;用药安全特点;治疗前后的炎性指标情况。结果莫西沙星治疗组急性肺脓肿治疗转归效果44例(97.78%)(显效36例,有效8例)高于头孢哌酮舒巴坦联合替硝唑治疗组31例(68.89%)(显效19例,有效12例),P <0.05。莫西沙星治疗组退热时间、恢复正常血常规时间、致病菌清除时间短于头孢哌酮舒巴坦联合替硝唑治疗组,P <0.05;莫西沙星治疗组用药安全特点和头孢哌酮舒巴坦联合替硝唑治疗组无明显差异,P> 0.05。治疗前两组炎性指标情况并无明显差异,P> 0.05;治疗后莫西沙星治疗组炎性指标情况优于头孢哌酮舒巴坦联合替硝唑治疗组,P <0.05。结论莫西沙星治疗急性肺脓肿效果肯定,可以有效控制炎症水平,清除致病菌,加速症状消失,促使血常规恢复到正常水平,无明显不良反应,值得推广应用。
Objective To investigate the clinical efficacy and safety of moxifloxacin and cefoperazone sulbactam combined with tinidazole in the treatment of acute pulmonary abscess. Methods Ninety patients with acute pulmonary abscess from January 2017 to April 2018 were divided into two groups according to the random number table method. The cefoperazone sulbactam combined with tinidazole group was treated with cefoperazone sulbactam combined with tinidazole, while the moxifloxacin group was treated with moxifloxacin. The outcome of acute lung abscess treatment was compared between two groups. Antipyretic time, normal blood routine time and pathogenic bacteria removal time;Characteristics of medication safety;Inflammatory indicators before and after treatment. Results The outcome of moxifloxacin treatment group for acute lung abscess was 44 case(97.78%)(36 cases with significant effect, 8 cases with effective effect), higher than that of cefoperazone and sulbactam combined with tinidazole treatment group 31 case(68.89%)(19 cases with significant effect, 12 cases with effective effect), P<0.05. In moxifloxacin treatment group, the time of antipyretic, normal blood routine and pathogenic bacteria clearance was shorter than that in cefoperazone and sulbactam combined with tinidazole treatment group, P<0.05;There was no significant difference between the safety characteristics of moxifloxacin treatment group and cefoperazone sulbactam combined with tinidazole treatment group(P>0.05). There was no significant difference in inflammatory indicators between the two groups before treatment(P>0.05). After treatment, the inflammatory index of moxifloxacin treatment group was better than that of cefoperazone and sulbactam combined with tinidazole treatment group, P<0.05. Conclusion Moxifloxacin is effective in the treatment of acute lung abscess. It can effectively control the level of inflammation, remove pathogenic bacteria, accelerate the disappearance of symptoms, and promote the blood routine to return to the normal level without
作者
刘敏
LIU Min(Tieling Tuberculosis Hospital,Tieling 112000,China)
出处
《中国医药指南》
2020年第21期53-54,共2页
Guide of China Medicine
